Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD

Respiratory Medicine

Volumn 107, Issue 12, 2013, Pages 1957-1965

  Gelb, Arthur F ^a   Tashkin, Donald P ^b   Make, Barry J ^c   Zhong, Xiaoyun ^d   Garcia Gil, Esther ^e   Caracta, Cynthia ^d  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e Almirall SA ^*  (Spain)

Author keywords

Aclidinium; Bronchodilation; COPD; Health status; Safety; Tolerability

Indexed keywords

ACLIDINIUM BROMIDE;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; DYSPNEA; EXTRASYSTOLE; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INSOMNIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SGRQ SCORE; SIDE EFFECT; SINUS BRADYCARDIA; SINUSITIS; SPIROMETRY; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; XEROSTOMIA;

ACLIDINIUM; BRONCHODILATION; COPD; HEALTH STATUS; SAFETY; TOLERABILITY;

ADMINISTRATION, INHALATION; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG REPOSITIONING; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART DISEASES; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; TROPANES;

EID: 84890314307     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.07.001     Document Type: Article

References (36)

1. World Health Organization. The global burden of disease: 2004 update. Available from: http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-full.pdf [accessed 21.12.2011].
2. National Heart, Lung and Blood Institute. Morbidity and mortality: 2009 chartbook on cardiovascular, lung and blood diseases. Available from: http://www.nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf [accessed 04.09.2011].
3. A.D. Lopez, K. Shibuya, C. Rao, C.D. Mathers, A.L. Hansell, and L.S. Held Chronic obstructive pulmonary disease: current burden and future projections Eur Respir J 27 2 2006 397 412
4. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 11 2006 e442
5. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, and A. Anzueto Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary Am J Respir Crit Care Med 187 4 2013 347 365
6. S.I. Rennard COPD heterogeneity: what this will mean in practice Respir Care 56 8 2011 1181 1187
7. F.M. Franssen, M.A. Spruit, and E.F. Wouters Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 6 2011 493 501
8. N.A. Hanania, G. Sharma, and A. Sharafkhaneh COPD in the elderly patient Semin Respir Crit Care Med 31 5 2010 596 606
9. R. Fuhr, H. Magnussen, K. Sarem, A.R. Llovera, A.M. Kirsten, and M. Falques Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD Chest 141 3 2012 745 752
10. P.W. Jones, D. Singh, E.D. Bateman, A. Agusti, R. Lamarca, and G. de Miquel Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur Respir J 40 4 2012 830 836
11. E.M. Kerwin, A.D. D'Urzo, A.F. Gelb, H. Lakkis, E. Garcia Gil, and C. Caracta Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I) COPD 9 2 2012 90 101
12. D. Singh, H. Magnussen, A. Kirsten, S. Mindt, C. Caracta, and B. Seoane A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients Pulm Pharmacol Ther 25 3 2012 248 253
13. J. Alberti, A. Martinet, S. Sentellas, and M. Salva Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide Drug Metab Dispos 38 7 2010 1202 1210
14. S. Sentellas, I. Ramos, J. Alberti, M. Salva, F. Anton, and M. Miralpeix Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites Eur J Pharm Sci 39 5 2010 283 290
15. M. Decramer, W. Janssens, and M. Miravitlles Chronic obstructive pulmonary disease Lancet 379 9823 2012 1341 1351
16. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, and P. Calverley Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 6 2007 532 555
17. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and A. Coates Standardisation of spirometry Eur Respir J 26 2 2005 319 338
18. P.W. Jones St. George's respiratory questionnaire: MCID COPD 2 1 2005 75 79
19. F. Holguin, E. Folch, S.C. Redd, and D.M. Mannino Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001 Chest 128 4 2005 2005 2011
20. C. Terzano, V. Conti, F. Di Stefano, A. Petroianni, D. Ceccarelli, and E. Graziani Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study Lung 188 4 2010 321 329
21. A.A. Dalal, M. Shah, O. Lunacsek, and N.A. Hanania Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease Respir Med 105 10 2011 1516 1522
22. J.M. Jansat, R. Lamarca, G. de Miquel, A. Schrodter, B. Miletzki, and M. Gurniak Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants J Clin Pharmacol 49 10 2009 1239 1246
23. J.M. Jansat, R. Lamarca, E. Garcia Gil, and P. Ferrer Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects Int J Clin Pharmacol Ther 47 7 2009 460 468
24. K. Lasseter, S. Dilzer, J.M. Jansat, E. Garcia Gil, C. Caracta, and S. Ortiz Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers Pulm Pharmacol Ther 25 2 2012 193 199
25. K.C. Lasseter, J. Aubets, F. Chuecos, and Gil E. Garcia Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects J Clin Pharmacol 51 6 2011 923 932
26. S. Singh, Y.K. Loke, P. Enright, and C.D. Furberg Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications Thorax 68 1 2013 114 116
27. D.E. Hilleman, M.A. Malesker, L.E. Morrow, and D. Schuller A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD Int J Chron Obstruct Pulmon Dis 4 2009 253 263
28. S.S. Ogale, T.A. Lee, D.H. Au, D.M. Boudreau, and S.D. Sullivan Cardiovascular events associated with ipratropium bromide in COPD Chest 137 1 2010 13 19
29. B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D.P. Tashkin Cardiovascular safety of tiotropium in patients with COPD Chest 137 1 2010 20 30
30. P. de Lucas-Ramos, J.L. Izquierdo-Alonso, J.M. Rodriguez-Gonzalez Moro, J.F. Frances, P.V. Lozano, and J.M. Bellon-Cano Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study) Int J Chron Obstruct Pulmon Dis 7 2012 679 686
31. J.D. Maclay, and W. MacNee Cardiovascular disease in COPD: mechanisms Chest 143 3 2013 798 807
32. Spiriva [package insert] July 2011 Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield, CT
33. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, G. San Pedro, and R.L. ZuWallack A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2 2002 217 224
34. B.J. Make Chronic obstructive pulmonary disease: developing comprehensive management Respir Care 48 12 2003 1225 1234 discussion 34-7
35. J. Bourbeau, and S.J. Bartlett Patient adherence in COPD Thorax 63 9 2008 831 838
36. C. Tantucci, and D. Modina Lung function decline in COPD Int J Chron Obstruct Pulmon Dis 7 2012 95 99